 |
Chronic Management of Obesity: A Comprehensive Approach to Reducing CV Risk CME Richard W. Nesto, MD, Chair; Louis J. Aronne, MD, FACP; Gregg C. Fonarow, MD; Luc F. Van Gaal, MD, PhD Author Information and Disclosures Release Date: May 27, 2008; Valid for credit through May 27, 2009 | Physicians - maximum of 1.75 AMA PRA Category 1 Credit(s)™ for physicians | | This CME activity is based on transcripts and slides of presentations as delivered by the faculty at the "Chronic Management of Obesity: A Comprehensive Approach to Reducing CV Risk" symposium held at the Hyatt Regency Chicago in Chicago, Illinois, on March 30, 2008. Contents of This CME Activity- Epidemiology and Pathophysiology of ObesityRichard W. Nesto, MDAvailable As: Slides/Audio | Slides/Transcript | Audio
- A Practical Approach to Reducing Obesity-Related Cardiovascular RiskGregg C. Fonarow, MDAvailable As: Slides/Audio | Slides/Transcript | Audio
- The Endocannabinoid System: A Novel Pathway in the Pathophysiology of ObesityLuc F. Van Gaal, MD, PhDAvailable As: Slides/Audio | Slides/Transcript | Audio
- Pharmacotherapeutic Approaches to the Clinical Management of ObesityLouis J. Aronne, MD, FACPAvailable As: Slides/Audio | Slides/Transcript | Audio
- Panel DiscussionRichard W. Nesto, MD; Gregg C. Fonarow, MD; Luc F. Van Gaal, MD, PhD; Louis J. Aronne, MD, FACPAvailable As: Slides/Audio | Slides/Transcript | Audio
Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 SciMed |
|
|
Learning Objectives Upon completion of this activity, participants should be able to: - Discuss the role of the cardiologist in the management of patients with obesity.
- Describe the involvement of the endocannabinoid system in the physiologic
and behavioral processes that contribute to obesity.
- Design and implement clinical strategies for the management of chronic obesity as a comprehensive approach to cardiovascular risk reduction.
Author Disclosures Louis J. Aronne, MD, FACP
Grants/Research
Support: Amylin Pharmaceuticals, Arena, Medtronic, Merck & Co., Inc., Medacure Inc., Obecure, Orexigen, Pfizer Inc, sanofi-aventis, VIVUS, Inc.; Consultant: Amylin Pharmaceuticals, Genaera, GlaxoSmithKline, Merck & Co., Inc., Orexigen, Pfizer Inc; Speakers Bureau: Pfizer Inc, sanofi-aventis
Gregg C. Fonarow, MD
Consultant: Merck & Co., Inc., Schering-Plough; Speakers Bureau: Merck & Co., Inc.,
Schering-Plough
Richard W. Nesto, MD
Speakers Bureau: sanofi-aventis
Luc F. Van Gaal, MD, PhD
Grants/Research Support: Merck & Co., Inc., sanofi-aventis; Speakers Bureau: Merck & Co., Inc., sanofi-aventis
|
 |
SciMed is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
SciMed designates this educational activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
